anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
963,439. Extracting bee venom. D. J. PALMER. May 1, 1962 [May 19, 1961], No. 18244/61. Heading A5B. An apparatus in which bees are collected and their venom obtained comprises a magazine 10 supported above the combs 11 of the hive 12 in association with a bee escape 13 with shutter 14. One face 15 of the magazine is a fine nylon mesh screen and the other face 17 is a glass panel slidably mounted in frame 16 and associated with a shutter 18 which, when opened, admits light into the hive and allows the bees to enter the magazine. For collecting the venom, the magazine may be removed from the hive and placed with face 15 in contact with the collector (see Fig. 2) which comprises a vessel 20 (e.g. of glass) with an upper face 23 of thin silicone rubber on which is placed a sheet of thin, wet tissue paper 26 on which rests an electric shock producing unit comprising a number of fine wires 29 connetted alternately to the live and neutral leads 28 from an A.C. source and mounted on a frame 27. Passage of the electric current causes the bees to sting through the fabric mesh, conductor, tissue paper and silicone rubber from which the stings may be withdrawn leaving globules of pure venom on the underside of the rubber sheet from which it may be removed by washing with a suitable liquid, e.g. physiological saline which may be passed through the collecting vessel via tubes 25. Alternatively, the rubber sheet may be dried and the crystalline venom may then be removed mechanically. Fig. 3 shows an alternative arrangement of the apparatus wherein the collector and associated equipment are placed on top of the magazine whilst it is still connected with the hive.
Patients undergo core biopsy, clinical, and blood sample collection as in Cohort I. Patients who have BIRADS 4b, 4c, and 5 lesions may undergo up to 6 additional 6 core biopsies.
Ossification of sacrospinous ligament induces a great risk for maintaining the stability of the pelvis. The sacrospinous ligament, along with the sacrotuberous ligament, plays a distinct role in the sacroiliac joint and pubic symphysis stability. The ossification may cause compression of neurovascular structure traversing through the greater and lesser sciatic foramen. Here we report a case of unilateral heterogenous ossification of the left sacrospinous ligament causing sciatic nerve compression and sciatic pain. A 22-year-old Bangladeshi woman, mother of one child, presented with complaints of pain in the lower back, left buttock and back of the upper thigh. Clinical examination and investigations revealed a diagnosis of the partially ossified sacrospinous ligament with sciatic nerve compression. Total excision of heterotrophic calcification and partial excision of left sacrospinous ligament through posterior approach by a left paramedian incision over the lower back was performed under general anaesthesia. On outpatient follow-up visits at 2 weeks and 6 weeks post-surgery, complete disappearance of pain was observed, and the patient was able to return to regular productive life activity. In this report, we presented a rare case of ossified sacrospinous ligament causing sciatic nerve compression with unknown etiology. The surgical approach performed, total excision of heterotrophic calcification and partial excision of left sacrospinous ligament through the posterior approach helped to preserve the pelvic stability with a good clinical outcome.
Constipation represents one of the five most common physician diagnoses for gut disorders. Obstructed defecation syndrome (ODS) is an under-treated condition which accounts for 30%- 50% of all patients with constipation and it is more common as people age. ODS is due to the abnormal contraction of the puborectalis muscle (a muscle around the anus that should relax during defecation).

Biofeedback therapy and medical management are the standards of care for ODS. Typically patients are first managed with dietary modifications (fiber supplementation, increased fluids) and medication (laxatives, enemas). If constipation is not improved, they will undergo biofeedback, which lasts from 3-8 sessions on average. Biofeedback acts on the cause of ODS and it has good short-term success, but around 50%-70% of treated patients re-experience constipation after one year. The main drawbacks of biofeedback for ODS are the facts that it is expensive, time-consuming, available in few select-centers and its success depends very much on the provider. Biofeedback is delivered in multiple 1-hour clinic sessions, so many patients don't finish all recommended sessions and their constipation may recur faster.

Botox also acts on the cause of ODS and was shown to improve constipation within 1-3 weeks after the injection. Botox is delivered as a one-time injection in the puborectalis muscle and external anal sphincter (the muscle right around the anus). The injection can be performed in the clinic under local anesthesia, and the patient goes home afterwards. Currently, Botox is used for treatment of patients who fail biofeedback and medical management, to avoid the options of last resort (resection of the colon with stoma). To this day, no adequately designed study has confirmed that Botox is indeed superior to placebo (normal saline) for the treatment of ODS. The results from this study will provide valuable data on the ability of Botox to improve symptoms of constipation and the duration of its effect. This project has the potential to increase the availability of effective treatments for ODS.
The invention relates to the technical field of biomedical gene therapy, and discloses an EMC1 nucleotide sequence and application thereof. The nucleotide sequence of the invention has more than or equal to 95 percent of sameness with the nucleotide sequence shown in SEQ ID NO. 3. The invention proves that the efficiency of the EMC1 coding sequence expression protein after codon optimization is higher than that of a wild type sequence, and abnormal changes of the transmembrane protein of the retinal cell caused by EMC1 mutation can be obviously improved by using AAV2-EMC1 drug treatment. EMC 1-knocked-down retinal pigment epidermal cells are treated with a drug, EMC1 can be efficiently expressed in the cell line, transmembrane protein folding errors in the cells are reduced, and normal functions of the transmembrane proteins in the retinal pigment epidermal cells are restored. Therefore, the AAV2-EMC1 medicine has the effect of preventing or treating retinitis pigmentosa.
Disclosed herein are new compositions comprising a purified cannabinoid and a purified terpene. In one embodiment, the compositions comprise one or more purified cannabinoids. In one embodiment, the compositions comprise one or more purified cannabinoids in combination with one or more purified terpenes. In one embodiment, the compositions comprise unnaturally occurring ratios. In one embodiment, the compositions comprise unnaturally occurring concentrations. In one embodiment, the compositions comprise unexpected and/or synergistic effects.
BACKGROUND: Recessive dystrophic epidermolysis bullosa (RDEB) is a blistering disease caused by mutations in the gene encoding type VII collagen (C7). RDEB is associated with fibrosis, which is responsible for severe complications. The phenotypic variability observed in siblings with RDEB suggests that epigenetic modifications contribute to disease severity. Identifying epigenetic changes may help to uncover molecular mechanisms underlying RDEB pathogenesis and new therapeutic targets.
OBJECTIVES: To investigate histone acetylation in RDEB skin and to explore histone deacetylase inhibitors (HDACi) as therapeutic molecules capable of counteracting fibrosis and disease progression in RDEB mice.
METHODS: Acetylated histone levels were detected in human skin by immunofluorescence and in RDEB fibroblasts by enzyme-linked immunosorbent assay (ELISA). The effects of givinostat and valproic acid (VPA) on RDEB fibroblast fibrotic behaviour were assessed by a collagen-gel contraction assay, Western blot and immunocytofluorescence for α-smooth muscle actin, and ELISA for released transforming growth factor (TGF)-β1. RNA sequencing was performed in HDACi- and vehicle-treated RDEB fibroblasts. VPA was systemically administered to RDEB mice and effects on overt phenotype were monitored. Fibrosis was investigated in the skin using histological and immunofluorescence analyses. Eye and tongue defects were examined microscopically. Mass spectrometry proteomics was performed on skin protein extracts from VPA-treated RDEB and control mice.
RESULTS: Histone acetylation decreases in RDEB skin and primary fibroblasts. RDEB fibroblasts treated with HDACi lowered fibrotic traits, including contractility, TGF-β1 release and proliferation. VPA administration to RDEB mice mitigated severe manifestations affecting the eyes and paws. These effects were associated with fibrosis inhibition. Proteomic analysis of mouse skin revealed that VPA almost normalized protein sets involved in protein synthesis and immune response, processes linked to the increased susceptibility to cancer and bacterial infections seen in people with RDEB.
CONCLUSIONS: Dysregulated histone acetylation contributes to RDEB pathogenesis by facilitating the progression of fibrosis. Repurposing of HDACi could be considered for disease-modifying treatments in RDEB.
Multimodal training (MT) will combine cardiovascular and resistance training interventions using the modalities described previously, but each component will be shortened to match the overall training duration (i.e., volume) among groups. The first part of each training session will always include three resistance exercises, which will be followed by 15-20 minutes of cardiovascular training performed on the total body recumbent stepper. Periodization will follow the same progression previously described for cardiovascular and resistance training, respectively, reaching vigorous intensity towards the end of the training period. Training sessions will include a five-minute warm-up and cool-down on the total body recumbent stepper. MT's sessions will approximately last 45 minutes (40 to 50 minutes) and will be interspersed with 48 hours of recovery.
FIELD: medicine, gastroenterology, chemical-pharmaceutical industry, phytotherapy. SUBSTANCE: invention relates to preparing medicinal species of plant raw origin that can be used for treatment of patients with large intestine sicknesses. Proposed species has mountain cranberry leaves, bur-marigold herb, matricary flowers, peppermint leaves taken at the definite ratio. Species shows clinical effect at chronic colitis and irritable colon syndrome but without significant stimulation of intestine motor activity (by electroenterography data). EFFECT: enhanced effectiveness of species proposed. 1 cl, 5 tbl
Sphingolipids (SLs) are vital constituents of the plasma membrane of animal cells and concurrently regulate numerous cellular processes. An escalating number of research have evinced that SLs assume a crucial part in the progression of tissue fibrosis, a condition for which no efficacious cure exists as of now. Cardiac fibrosis, and in particular, atrial fibrosis, is a key factor in the emergence of atrial fibrillation (AF). AF has become one of the most widespread cardiac arrhythmias globally, with its incidence continuing to mount, thereby propelling it to the status of a major public health concern. This review expounds on the structure and biosynthesis pathways of several pivotal SLs, the pathophysiological mechanisms of AF, and the function of SLs in cardiac fibrosis. Delving into the influence of sphingolipid levels in the alleviation of cardiac fibrosis offers innovative therapeutic strategies to address cardiac fibrosis and AF.
An estimated 1 in 2 US adults will have obesity by 2030, which is a major cause of morbidity and mortality. The highest risk of weight gain is among young adults ages 18-35 years. In-person behavioral interventions generally produce clinically significant weight losses, but cost and reduced reach limit their ability to impact obesity at a population level. Web-based interventions that mimic the structure of weekly face-to-face treatment have proven a viable alternative, though weight losses are generally smaller than in-person treatment. Mobile treatments have the potential for high reach, but have been less effective, producing 1-3 kgs over 6 months. Newer digital intervention approaches called "just-in-time adaptive interventions" (JITAIs) promise to improve upon mobile outcomes by offering adaptive, personalized feedback on behavior, which consists of providing the "right type of support" at "the right time" rather than on a fixed schedule. This "just-in- time," or JIT, approach is made possible by the emergence of low-cost and widely available digital health tools that allow for the collection of continually updated health data. However, to date, no JITAIs have successfully targeted multiple weight-related behaviors (weighing, activity, and diet), and there has been no systematic examination of what types of messaging interventions best promote adherence to these three weight loss behaviors, for whom they are effective, and under what conditions. To address this problem, a micro-randomized trial will be used to evaluate the effects of 7 types of intervention messages targeting specific behavior change techniques (i.e., BCT messages) delivered in JIT moments on daily achievement of behavioral goals among n=201 young adults with overweight and obesity. All participants will receive a 6-month behavioral weight loss intervention using our Nudge mobile app, which includes evidence-based weekly lessons, tailored feedback, self-monitoring, and daily BCT messages. Participants will receive a wireless scale, activity tracker, and track "red" foods (high-calorie foods) in the app and have 3 goals: weigh daily, a daily active minutes goal that gradually increases if met, and a daily red foods limit. At 3 decision points per day, participants will be micro-randomized to receive or not receive 1 of 7 types of BCT messages. Each intervention message has unique decision rules for availability. Candidate intervention message options have been carefully selected from empirical evidence, tested in our prior studies, or are from our pilot micro-randomized trial. Assessments will occur daily, and at 0, 3 and 6 months, to accomplish the following specific aims: 1) Evaluate the effects of each behavior change technique message (i.e., BCT message) on daily adherence to weight loss behaviors; 2) Determine whether the effects of BCT messages on proximal outcomes change over time; and 3) Assess whether the effects of BCT messages on proximal outcomes are moderated by participants' contextual factors. Findings will guide how adaptive, behaviorally- and contextually-dependent messages are incorporated into future JITAIs for weight loss.
In adult patients with transfusion dependent beta thalassemia, EMH masses were observed in 3.2% of REBLOZYL-treated patients, with spinal cord compression symptoms due to EMH masses occurring in 1.9% of patients (BELIEVE and REBLOZYL long-term follow-up study).

In a study of adult patients with non-transfusion dependent beta thalassemia, a higher incidence of EMH masses was observed in 6.3% of REBLOZYL-treated patients vs. 2% of placebo-treated patients in the double-blind phase of the study, with spinal cord compression due to EMH masses occurring in 1 patient with a prior history of EMH. REBLOZYL is not indicated for use in patients with non-transfusion dependent beta-thalassemia.

Possible risk factors for the development of EMH masses in patients with beta thalassemia include history of EMH masses, splenectomy, splenomegaly, hepatomegaly, or low baseline hemoglobin (<8.5 g/dL). Signs and symptoms may vary depending on the anatomical location. Monitor patients with beta thalassemia at initiation and during treatment for symptoms and signs or complications resulting from the EMH masses and treat according to clinical guidelines. Discontinue treatment with REBLOZYL in case of serious complications due to EMH masses. Avoid use of REBLOZYL in patients requiring treatment to control the growth of EMH masses.
This is a split body study in which all subjects will receive bilateral flank treatment with CoolSculpting. The investigator will determine one flank for treatment using the CoolCore applicator without an accessory for a duration of 60 minutes at a protocol-defined temperature. The contralateral flank will be treated with the standard CoolCore Applicator using an applicator accessory, the Crown Cooling Insert (CCI) at a protocol-defined temperature for a duration of up to 45 minutes. All enrolled subjects receive identical treatments; the investigator will use alternate subject numbers to balance which flank to treat with and without the CoolCore applicator accessory, such that all even subject numbers will receive treatment using the Standard CoolCore on the right flank and odd subject numbers will receive the same treatment on the left flank.
A data processing system to determine a risk factor of an impending transfer to the emergency department of an individual. The system includes a database which stores a plurality of status records for each person of a set of people. Each status record is dated and includes a list of monitoring indicators. Each indicator has a value chosen from a list of two predetermined values according to the status of the corresponding person. The system also a microprocessor to determine the risk factor by analyzing a plurality of status records of the individual, filled out according to the status of the individual, using a machine learning algorithm. The parameters of the algorithm being generated beforehand. A data processing method is further provided to determine a risk factor for an impending transfer of the individual to the emergency department.
The parent specification discloses a dental compsn. based on an amalgam prepd. by mixing amalgam filings with Hg, and hardening the mixt. at body temp., the compsn. being a dispersion-strengthened amalgam in which the non-amalgamated particles do not contact each other. An improvement in corrosion resistance of the compsn. is now obtd. by using a Ag-Sn-Cu alloy for the dispersion-strengthening skeleton. Pref. the dispersion-strengthening skeleton as well as the filings, which form the matrix are composed of an Ag-Sn-Cu alloy, the skeleton alloy having a higher Cu content than the matrix alloy. The higher Cu content may be produced by coating the particles of the Ag-Sn-Cu alloy with a thin layer of Cu either chemically or electrolytically. The alloy may also contain Zn and/or Au and/or Cd.
The invention discloses METTL gene inhibitor and application thereof, and relates to the field of molecular biology. The inhibitor is one of siRNA, shRNA or METTL gene interference slow virus for inhibiting METTL gene expression; wherein, the target sequence of the siRNA is shown as SEQ ID NO.1 or SEQ ID NO. 2; the sense strand of the shRNA nucleotide sequence is shown as SEQ ID NO.3, and the antisense strand is shown as SEQ ID NO. 4; or the sense strand is shown as SEQ ID NO.5, and the antisense strand is shown as SEQ ID NO. 6. The inhibitor can effectively inhibit METTL gene expression, has higher inhibition efficiency on cell proliferation, cell migration and invasion of cancer cells, and has good drug development prospect.
Patients with Adenocarcinoma will be included. They will have blood sample at the inclusion visit and at 3 months, 6 months, 9 months and 12 months after.
PROBLEM TO BE SOLVED: To make it possible to lessen the clogging of a dental wheel at the time of grinding, to enhance its grinding efficiency and to improve the shape and dimensional accuracy at the time of cutting by incorporating a prescribed range of Cu into the above alloy, consisting of the balance Ti and inevitable impurities and improving machinability as well. SOLUTION: The dental free-cutting titanium alloy contains 2 to 15 wt.% Cu, is composed of the balance the Ti and the inevitable impurities and has the excellent machinability. This titanium alloy has the structure of αTi+Ti2Cu as Ti+Ti2Cu deposits in a lamella form by an eutectic reaction. This Ti+Ti2Cu which is an intermetallic compound has a brittle characteristic and, therefore, improves the crushing characteristic of chips at the time of grinding, cutting, etc. The clogging of the dental wheel (grinding wheel) at the time of grinding may, therefore, be lessened and the improvement in the shape and dimensional accuracy at the time of cutting is made possible. Then, a casting material of the titanium alloy practically usable in carrying out a dental treatment may be obtained.
The present disclosure relates to methods for modulating cellular aging and/or progression of neurodegenerative diseases (e.g., AD). In certain embodiments, the methods induce cellular aging. In certain embodiments, the methods promote progression of neurodegenerative diseases (e.g., AD). The present disclosure also relates to methods and systems for modeling aging related neurodegenerative diseases (e.g., AD) in vitro. In certain embodiments, the methods disclosed herein comprise inhibiting protein neddylation pathway. In certain embodiments, inhibiting protein neddylation pathway comprises knocking out or knocking down genes (e.g., UBA3, NAE1) that regulate protein neddylation pathway. In certain embodiments, inhibiting protein neddylation pathway comprises administration a neddylation inhibitor (e.g., MLN4924) to cells.
Superficial venous reflux is common in adult population. Uncomplicated disease, where there is no skin changes but varicose veins with or without leg swelling, can be totally asymptomatic but also cause various symptoms as pain, aching and discomfort of leg usually caused by increased venous pressure. Varicose veins may also cause cosmetic problem. Compression stockings relief the symptoms as they normalize venous pressure. In surgical treatment, axial reflux is treated usually by removing incompetent superficial veins. The aim of the study is to compare conservative treatment with compression stockings with surgical treatment of superficial venous reflux. In operative treatment the great saphenous vein or lesser saphenous vein are removed after flush ligation by femoral vein and stripping of the trunk. If the main trunk has been removes previously, axial refluating veins are removed or ligated according to the DUS finding. The patients in both groups are examined at the baseline and followed up to two years by ultrasound scanning. Patients clinical classification, venous disability score, venous disease severity score, anatomical path of reflux as well as quality of life are studied at the baseline, at one year follow-up and two years follow-up.
Although most primary central and peripheral nervous system (NS) tumors occur sporadically, there are a subset that may arise in the context of a cancer predisposition syndrome. These syndromes occur due to a pathogenic mutation in a gene that normally functions as a tumor suppressor. With increased understanding of the molecular pathogenesis of these tumors, more people have been identified with a cancer predisposition syndrome. Identification is crucial, as this informs surveillance, diagnosis, and treatment options. Moreover, relatives can also be identified through genetic testing. Although there are many cancer predisposition syndromes that increase the risk of NS tumors, in this review, we focus on three of the most common cancer predisposition syndromes, neurofibromatosis type 1, neurofibromatosis type 2, and tuberous sclerosis complex type 1 and type 2, emphasizing the clinical manifestations, surveillance guidelines, and treatment options.